Question 1

What is the difference between Cortagen and Cortexin?

Accepted Answer

Cortexin is a polypeptide complex extracted from calf brain tissue containing hundreds of peptide fragments. Cortagen (AEDG) is a single synthetic tetrapeptide identified as the key regulatory sequence from that complex. Cortagen offers standardization and purity advantages over the tissue extract.

Question 2

Is Cortagen the same peptide sequence as Epithalon?

Accepted Answer

Yes, both share the AEDG sequence. The distinction made by Khavinson's group is tissue targeting — Epithalon is described as targeting pineal/telomerase pathways while Cortagen targets cortical neurons. Whether a four-amino-acid peptide can meaningfully target specific tissues remains debated.

Question 3

Can Cortagen help with post-stroke recovery?

Accepted Answer

Cortexin (the tissue extract) has been used in Russian clinical practice for stroke rehabilitation, with some positive published observations. Whether the single tetrapeptide Cortagen replicates the full extract's effects is unclear. No controlled post-stroke trials of Cortagen specifically have been published in English-language journals.

Question 4

How does Cortagen compare to Semax for cognitive enhancement?

Accepted Answer

Semax is a synthetic ACTH fragment with well-characterized neurotrophic and neurotransmitter effects. Cortagen works through a proposed epigenetic mechanism. Semax has more robust published data and a clearer pharmacological profile. Cortagen is more experimental.

Question 5

What is the safety profile of Cortagen?

Accepted Answer

As an ultra-short peptide composed of common amino acids, Cortagen has shown no significant adverse effects in published Russian studies. The safety profile appears favorable, though Western regulatory-grade safety data (Phase I/II) does not exist.

Question 6

What organ system does Cortagen target?

Accepted Answer

Cortagen was designed to specifically target the cerebral cortex — the outer layer of the brain responsible for higher cognitive functions including memory, attention, language, and decision-making. According to Khavinson's bioregulation theory, the AEDG peptide sequence preferentially modulates gene expression in cortical neurons. This tissue specificity is proposed to occur through selective interaction with chromatin in cortex-derived cells, though the exact mechanism by which a four-amino-acid peptide achieves tissue selectivity remains an open question in the field.

Question 7

How is Cortagen different from other bioregulators like Pinealon?

Accepted Answer

Cortagen (AEDG) and Pinealon (EDR) are both short synthetic peptides from the Khavinson bioregulator family, but they target different brain regions and functions. Cortagen is directed at the cerebral cortex and is studied for neuroprotection and cognitive performance, while Pinealon targets deeper brain structures involved in neurodegeneration and has been studied in models of Alzheimer-type pathology. Their amino acid sequences differ, and in preclinical studies they modulate distinct sets of genes. In practice, some bioregulator practitioners combine them for broader CNS support, though no controlled human trials have validated this combination approach.

Question 8

Can Cortagen be taken orally?

Accepted Answer

Yes, Cortagen is commonly available in oral capsule form (typically 10 mg), and sublingual administration is also used. Unlike larger peptides that are degraded in the gastrointestinal tract, ultra-short peptides like AEDG are proposed to survive digestion due to their small size and may be absorbed intact through the intestinal epithelium. Khavinson's research group has published data suggesting that short bioregulatory peptides (2-4 amino acids) retain biological activity when administered orally. However, oral bioavailability has not been rigorously quantified in pharmacokinetic studies meeting Western regulatory standards.

Question 9

What does the research show about Cortagen and brain aging?

Accepted Answer

Preclinical research from Khavinson's institute suggests Cortagen may counteract age-related changes in cortical gene expression, particularly genes involved in antioxidant defense (superoxide dismutase, catalase) and neurotrophic support (BDNF). In aged animal models, Cortagen administration was associated with reduced neuronal apoptosis and improved markers of synaptic plasticity. The parent extract Cortexin has more extensive data in elderly patients, with Russian clinical studies reporting improved cognitive scores and EEG normalization in geriatric cohorts. However, these findings have not been independently replicated outside of Russian research institutions, and no Western-standard randomized controlled trials exist for Cortagen specifically in brain aging.

Origin / Manufacturer	Synthetic
Active Components	Cortagen tetrapeptide (Ala-Glu-Asp-Gly)Mannitol (capsule filler)
Storage	Room temperature, protected from moisture and light
Shelf Life	36 months
Form Factor	Capsules (10 mg) or lyophilized powder

Cortagen

Specifications

Frequently Asked Questions

Related Peptides

Cerebrolysin

Epitalon

Pinealon

Semax